Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…
Merck Completes Acquisition of EyeBio
Merck, known as MSD outside of the United States and Canada, announced the successful completion of its acquisition of Eyebiotech Limited (EyeBio), marking EyeBio as a fully owned subsidiary of Merck. “The EyeBio acquisition further diversifies our late-stage pipeline with…
Genentech Reintroduces Susvimo Ocular Implant for Wet AMD
Genentech announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant, aimed at treating wet age-related macular degeneration (AMD). This decision follows the FDA’s approval of a post-approval supplement to the Biologics License Application, which…
Outlook Therapeutics Receives UK Approval of Lytenava for AMD
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava is the first and only authorized…
Glaukos Activates CMS J-Code for iDose TR
Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for its iDose TR product. This development marks a significant milestone in enhancing patient access and streamlining coverage and payment processes for the innovative treatment, according…
Rethinking Antibiotic Use in Pediatric Pink Eye Cases
In a recent study published in the journal JAMA Ophthalmology, researchers revealed troubling trends in the treatment of pink eye among children and teens in the United States. Despite guidelines from the American Academy of Ophthalmology discouraging the use of…
FDA Greenlights Formycon and Klinge’s Biosimilar to Eylea
Formycon AG and its licensing partner Klinge Biopharma GmbH announced the U.S. Food and Drug Administration’s (FDA) approval of FYB203/AHZANTIVE®, a biosimilar to Eylea®. FYB203/AHZANTIVE® has been approved by the FDA for the treatment of patients with Age-Related Neovascular (wet)…
Study Suggests Novel Treatment Approach for Wet AMD
A recent study conducted on mice has provided promising insights into a potential alternative treatment for the “wet” version of age-related macular degeneration (AMD). Researchers identified an enzyme, telomerase, which plays a critical role in the abnormal blood vessel growth…